This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 24 Oct 2018  |  North America  |  Mega Trends

    Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025

    A Robust Product Pipeline Creating Opportunities for Ground-breaking Combination Therapies is Set to Revolutionize the Global Cell Therapy Market

    The global pharmaceuticals industry is continuously evolving to meet the requirements of a changing disease landscape. With the increasing prevalence of chronic infectious diseases and cancer, market needs are shifting from traditional small molecules to novel large molecule therapies, with cell therapies dominating the space. This study presents a...

    $4,950.00
  2. 10 Jan 2018  |  Asia Pacific  |  Mega Trends

    APAC Biosimilar Market, Forecast 2025

    Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

    Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Ko...

    $4,950.00
  3. 27 Nov 2017  |  North America  |  Mega Trends

    Growth Opportunities in the Global Digital Pathology Market, Forecast to 2021

    New Business Models and More FDA Approvals of WSI Scanners for Primary Diagnostics are Set to Boost Growth of Digital Pathology

    Shortage of pathologists and the rise in new cancer cases are the key drivers for the adoption of digital pathology solutions globally. Digital pathology enhances the productivity of pathologists by 10% to 15%, thereby improving the overall efficiency of healthcare providers. Digital pathology solutions find the best fit in oncology care. Accordin...

    $4,950.00
  4. 19 Jun 2017  |  Asia Pacific  |  Mega Trends

    Growth Opportunities in the APAC IVD Market, Forecast to 2021

    Digital Pathology and Laboratory Automation are Two Strategic Themes Driving the Growth of the IVD Market

    The study aims to analyze and forecast the Asia Pacific (APAC) in-vitro diagnostics (IVD) market outlook and technology trends for 2016. Research Scope: • Key trends and opportunities in the IVD market, which has been segmented into 8 major divisions: o Immunochemistry o Self-monitoring Blood Glucose (SMBG) Meter o Hematology o Point-of-care...

    $4,950.00
  5. 23 May 2017  |  North America  |  Mega Trends

    Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021

    US IVD Market Witnesses Pricing Fluctuations Due to the PAMA Regulation

    The In Vitro Diagnostics (IVD) landscape in the United States is extremely dynamic, with a high level of merger and acquisition activity with many high-value deals still pending. Both clinical laboratories and manufacturers are increasingly vying for smaller specialized niche technology companies to increase their market share. Molecular point of c...

    $4,950.00